Product Overview
Key figures
Bonus amount per interval | 2.25% (22.50 CHF) |
Call interval (in months) | 3 |
Distance to Barrier | 24.20% |
Life Cycle
- Initial Fixing
- First trading day
- Today
- Last trading date
- Final fixing
- Redemption
Product performance (1D): –
| Graph | Underlying | Price (indicative) | Last Closing Price (indicative) | Performance | |
|---|---|---|---|---|---|
| - | Eli Lilly & Co. | 826.4500 USD | |||
| - | Novartis AG | 95.6583 CHF | |||
| - | Novo Nordisk A/S | 593.4874 DKK | |||
| - | Pfizer Inc. | 25.8630 USD |
Product Information
About this product
Like the classic version, Multi Callable Barrier Reverse Convertibles (BRCs) are characterized by a pre-determined coupon and a safety buffer up to the barriers. The callable attribute improves the yield because coupons are generally higher than for regular Multi BRCs, but investors bear the reinvestment risk if the products are redeemed ("called") early.